CXCR2 and neoplasm: Temozolomide (TMZ), a common alkylating agent used in adjuvant chemotherapy for HGG, has been shown to upregulate the CXCL8-dependent CXCL2/CXCR2 axis, promoting angiogenesis and the recruitment of tumor-associated macrophages.